RefleXion Receives Clearance from FDA for New X1 Machine
A significant stepping stone in radiotherapy occurred with the announcement by the therapeutic oncology company, RefleXion Medical. RefleXion Medical received clearance from the U.S. Food and Drug Administration (FDA) for three types of therapy; stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and intensity-modulated radiotherapy (IMRT). The groundbreaking new technology within the X1 machine will allow for more precise tumor location capabilities that can combine high-quality CT imaging. Within the X1 device, a linear accelerator offers technology that can rotate 60 times faster than standard linear devices. In this article, the CEO of RefleXion Medical is hoping that the X1 machine will treat not only the early stages of cancer but also offer thorough treatment solutions for those suffering from the most advanced stages. The transition of this company from a research-level, to now a commercial entity, has been a 10-year process. The company comes full circle by offering a new form of treatment with biology-guided radiotherapy (BgRT) into the market.